Patents by Inventor Howell F. Moffett

Howell F. Moffett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
    Patent number: 11872195
    Abstract: Compositions and methods that rapidly and selectively modify hematopoietic stem cells (or cells derived therefrom) to achieve therapeutic objectives by providing for transient expression of nucleic acids are described. The transient expression leads to permanent therapeutic changes in the modified cells, referred to herein as “hit and run” effects.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: January 16, 2024
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Matthias Stephan, Howell F. Moffett
  • SYSTEMS AND METHODS TO PRODUCE B CELLS GENETICALLY MODIFIED TO EXPRESS SELECTED ANTIBODIES
    Publication number: 20230250159
    Abstract: Systems and methods to genetically modify B cells to express selected antibodies are described. The systems and methods can be used to: obviate the need for classical vaccinations; provide protection against infectious agents for which no vaccinations are currently available; provide protection against infectious agents when patients are otherwise immune-suppressed; and/or provide a benefit provided by a therapeutic antibody, such as in the treatment of autoimmune disorders.
    Type: Application
    Filed: February 8, 2023
    Publication date: August 10, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Justin J. Taylor, Howell F. Moffett
  • Systems and methods to produce B cells genetically modified to express selected antibodies
    Patent number: 11578118
    Abstract: Systems and methods to genetically modify B cells to express selected antibodies are described. The systems and methods can be used to: obviate the need for classical vaccinations; provide protection against infectious agents for which no vaccinations are currently available; provide protection against infectious agents when patients are otherwise immune-suppressed; and/or provide a benefit provided by a therapeutic antibody, such as in the treatment of autoimmune disorders.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: February 14, 2023
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Justin J. Taylor, Howell F. Moffett
  • SYSTEMS AND METHODS TO PRODUCE B CELLS GENETICALLY MODIFIED TO EXPRESS SELECTED ANTIBODIES
    Publication number: 20210198344
    Abstract: Systems and methods to genetically modify B cells to express selected antibodies are described. The systems and methods can be used to: obviate the need for classical vaccinations; provide protection against infectious agents for which no vaccinations are currently available; provide protection against infectious agents when patients are otherwise immune-suppressed; and/or provide a benefit provided by a therapeutic antibody, such as in the treatment of autoimmune disorders.
    Type: Application
    Filed: October 19, 2018
    Publication date: July 1, 2021
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Justin J. Taylor, Howell F. Moffett
  • COMPOSITIONS AND METHODS TO PROGRAM THERAPEUTIC CELLS USING TARGETED NUCLEIC ACID NANOCARRIERS
    Publication number: 20190111153
    Abstract: Compositions and methods that rapidly and selectively modify hematopoietic stem cells (or cells derived therefrom) to achieve therapeutic objectives by providing for transient expression of nucleic acids are described. The transient expression leads to permanent therapeutic changes in the modified cells, referred to herein as “hit and run” effects.
    Type: Application
    Filed: December 17, 2018
    Publication date: April 18, 2019
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Matthias Stephan, Howell F. Moffett
  • Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
    Patent number: 10188749
    Abstract: Compositions and methods that rapidly and selectively modify hematopoietic stem cells (or cells derived therefrom) to achieve therapeutic objectives by providing for transient expression of nucleic acids are described. The transient expression leads to permanent therapeutic changes in the modified cells, referred to herein as “hit and run” effects.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: January 29, 2019
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Matthias Stephan, Howell F. Moffett
  • COMPOSITIONS AND METHODS TO PROGRAM THERAPEUTIC CELLS USING TARGETED NUCLEIC ACID NANOCARRIERS
    Publication number: 20170296676
    Abstract: Compositions and methods that rapidly and selectively modify hematopoietic stem cells (or cells derived therefrom) to achieve therapeutic objectives by providing for transient expression of nucleic acids are described. The transient expression leads to permanent therapeutic changes in the modified cells, referred to herein as “hit and run” effects.
    Type: Application
    Filed: May 12, 2017
    Publication date: October 19, 2017
    Inventors: Matthias Stephan, Howell F. Moffett